Annbjørg Falck presented the Norwegian company NaDeNo during the International Cancer Cluster Showcase 2023.

Oncology innovators presented in Boston

Three Nordic start-ups pitched at the International Cancer Cluster Showcase 2023.

This year’s International Cancer Cluster Showcase (ICCS) featured 20 emerging oncology companies that presented their recent innovations, partnering and investment opportunities on 5 June 2023 in Boston, as a satellite event to BIO International Convention. 

The companies were selected by innovation hubs in the United States (Massachusetts & Philadelphia), Quebec, Norway, the UK Golden Triangle, Switzerland, France, and Taiwan. 

“BIO International Convention is one of the largest gatherings of biotechnology and life sciences professionals from around the world. It provides an excellent platform for companies to network with potential partners, investors, customers, and collaborators. Via being part of the ICCS program emerging oncology companies get special visibility and exposure at the start of BIO. For those searching for collaboration, partnering and investment opportunities ICCS is an efficient format to meet 20 companies from international hubs and learn about their latest science, technologies, and (mostly preclinical) assets,” commented Jutta Heix, Head of International Affairs, Oslo Cancer Cluster and coordinator of the ICCS programme. 

Jutta Heix, Head of International Affairs at Oslo Cancer Cluster, welcomed the audience to the 12th International Cancer Cluster Showcase.

Promising Norwegian companies

NaDeNo, Hemispherian and One-Carbon Therapeutics represented the Nordic region during the event, which included four-minute pitches from each company. 

Attending the BIO International conference for the first time as a small Norwegian start-up we highly appreciated the opportunity to share our story to a larger audience! Being visible in this way accelerates new relationships and valuable networking, and it really kick-started the conference for us. Many thanks to OCC for giving us this opportunity,” commented Annbjørg Falck, CEO and co-founder of NaDeNo.  

Adam Robertson, CSO of Hemispherian, presented one of the Nordic companies.

“The International Cancer Cluster Showcase presents a tremendous opportunity for Hemispherian to showcase our pharmaceutical development program on a global stage. This international exposure serves to highlight the exceptional nature of our technology and the expertise of our team. We are thrilled to have the privilege of presenting alongside other outstanding companies, which also provides us with a platform to showcase the rapidly growing Norwegian biotechnology sector. The event allows us to further establish Hemispherian’s reputation, attract attention to our innovative approach, and foster collaborations in the fight against cancer,” commented Adam Robertson, CSO of Hemispherian. 

Returning to Boston

This was the 12th edition of the International Cancer Cluster Showcase. Since 2012, the event has presented about 200 oncology start-ups and biotech companies as a satellite event to BIO International Convention and now returned to Boston where this format was started. The event connects emerging oncology companies from different innovation hubs with potential partners from the global oncology community gathering at BIO. 

The International Cancer Cluster Showcase 2023 was organized by Cambridge Innovation Partners, Montréal InVivo, The Wistar Institute, Oslo Cancer Cluster, OBN, Biopôle and Matwin. 

The event was kindly sponsored by Precision for Medicine, BIO and The Wistar Institute. 



The post Oncology innovators presented in Boston first appeared on Oslo Cancer Cluster.